Max Healthcare Institute Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing a Max Healthcare Institute target price for 2027 should start with where the stock sits today. At Rs 883.80 on 9 October 2026, it is 27.7% below its 52-week high of Rs 1,221.90 and 1.6% above its 52-week low of Rs 870.00. That range spans 40% from low to high, so the entry point matters as much as the Max Healthcare Institute price forecast itself.

This article builds the Max Healthcare Institute share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 1,023 base case and the Rs 1,237 bull case were reached, along with a downside risk level of Rs 701.

Click Here – Get Free Investment Predictions

Max Healthcare Institute Stock Analysis: Company Overview and Key Stats

Max Healthcare Institute (NSE: MAXHEALTH) has a market capitalisation of Rs 85,291 crore. In FY26 it reported revenue of Rs 8,536 crore and net profit of Rs 1,442 crore. The table collects the figures the Max Healthcare Institute share price target is built on.

Metric	Value
Company	Max Healthcare Institute
NSE Ticker	MAXHEALTH
CMP (9 October 2026)	Rs 883.80
52-Week High	Rs 1,221.90
52-Week Low	Rs 870.00
Market Cap	Rs 85,291 crore
PE Ratio (TTM)	58.54
Industry PE	62.79
Price to Book	7.94
Return on Equity	13.42%
Debt to Equity	0.32
EPS (TTM)	Rs 14.97
Dividend Yield	0.23%
12-Month Base Target	Rs 1,023
Bull Case	Rs 1,237
Downside Risk Level (not a target)	Rs 701

Why Is Max Healthcare Institute Share Price Target Set at Rs 1,023 for 2027?

The base-case Max Healthcare Institute stock target of Rs 1,023 applies a PE multiple of 58.54 to a forward EPS estimate of Rs 17.47. That EPS assumes 16.7% yearly growth, the pace from FY24 to FY26, and puts the target 15.8% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Max Healthcare Institute Target Price: Five Years of Results

Max Healthcare Institute grew revenue from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew faster, from Rs 605.05 crore to Rs 1,442 crore (24.3% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	4,058.82	605.05	6.24	0.00
FY23	4,701.84	1,103.51	11.36	1.00
FY24	5,582.96	1,057.64	10.84	1.50
FY25	7,184.10	1,075.88	11.01	1.50
FY26	8,536.07	1,442.41	14.76	2.00

FY26 revenue growth was 18.8%, close to the four-year average of 20.4%, and net profit moved up 34.1%. EPS rose from Rs 10.84 in FY24 to Rs 14.76 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Max Healthcare Institute converted 16.9% of FY26 revenue into net profit, against 15.0% in FY25, within a five-year range of 14.9% to 23.5%. EBITDA margin was 27.6% in FY26 versus 26.9% in FY25.

In the June 2026 quarter, revenue was Rs 2,407 crore, up 16.6% from the same quarter a year earlier, while net profit of Rs 322.96 crore was up 4.9%. EBITDA came in at Rs 638.97 crore, up 14.2% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.32, and shareholders' equity grew from Rs 6,282 crore in FY22 to Rs 10,747 crore in FY26. Operating cash flow in FY26 was Rs 1,633 crore against capital expenditure of Rs 1,485 crore, leaving free cash flow of Rs 148.79 crore, or 0.2% of the current market capitalisation. In FY25 free cash flow was Rs 493.48 crore.

Valuation Check for the Max Healthcare Institute Stock Target: PE, Price to Book and ROE

At a PE of 58.54 against an industry PE of 62.79, Max Healthcare Institute trades in line with its industry. Price to book is 7.94 on a book value of Rs 110.39 per share, and return on equity is 13.42%. A PE of 58.54 equals an earnings yield of 1.7%, and the FY26 dividend of Rs 2.00 per share gives a yield of 0.23%.

Shareholding Pattern and Institutional Holding

Promoters held 23.71% of Max Healthcare Institute in June 2026, and promoter holding has stayed near 23.71% since June 2025. Foreign institutional investors (FII) held 41.78% and domestic institutions (DII) held 29.96%, which puts total institutional holding at 71.74%. FII holding fell from 54.76% in June 2025 to 41.78% in June 2026. Public shareholders own the remaining 4.56%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Max Healthcare Institute Share Price Targets for the Short Term and 12 Months

Short Term Max Healthcare Institute Stock Target Levels: Technical Setup

At Rs 883.80 on 9 October 2026, Max Healthcare Institute trades below its 50-day simple moving average of Rs 1,012.97 and below its 200-day exponential moving average of Rs 1,042.16. The 14-day RSI reads 18.3, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,012.97 (50-day simple moving average) and the nearest support is Rs 870.00 (52-week low). A sustained move above Rs 1,012.97 would improve the short-term setup, while a close below Rs 870.00 would shift attention to the next support.

12 Month Max Healthcare Institute Target Price for 2027

The 12-month target for Max Healthcare Institute is Rs 1,023: forward EPS of Rs 17.47 at a PE of 58.54. That is 15.8% above Rs 883.80. It would still leave the stock 16.3% below its 52-week high of Rs 1,221.90.

How EPS Growth and PE Multiple Change the Max Healthcare Institute Target Price

EPS Growth	PE 46.83	PE 58.54	PE 67.32
0.0% (EPS Rs 14.97)	Rs 701	Rs 876	Rs 1,008
16.7% (EPS Rs 17.47)	Rs 818	Rs 1,023	Rs 1,176
22.7% (EPS Rs 18.37)	Rs 860	Rs 1,075	Rs 1,237

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Max Healthcare Institute price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Max Healthcare Institute Stock Target in 2027

Bull Case Rs 1,237

The bull case Max Healthcare Institute price target needs EPS growth of 22.7%, which lifts forward EPS to Rs 18.37, and a PE multiple that rises 15% to 67.32. That gives Rs 1,237, 40.0% above the current price and above the 52-week high of Rs 1,221.90, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 701

The downside risk level is not a target. It assumes EPS stays flat at Rs 14.97 and the PE falls 20% to 46.83. That gives Rs 701, 20.7% below the current price and below the 52-week low of Rs 870.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	22.7%	67.32	Rs 1,237	+40.0%
Base Case	16.7%	58.54	Rs 1,023	+15.8%
Downside Risk	0.0%	46.83	Rs 701	-20.7%

Key Risks to the Max Healthcare Institute Target Price for 2027

Growth Slowdown Risk for the Max Healthcare Institute Price Target

Revenue in the June 2026 quarter was up 16.6% year on year, and FY26 revenue growth was 18.8%. If growth slows from here, the EPS estimate behind the Max Healthcare Institute stock target will need revising.

Liquidity and Size Risk

Max Healthcare Institute has a market capitalisation of Rs 85,291 crore. Institutional holding is 71.74%, and promoters hold 23.71%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.

Valuation and Margin Risk

Net margin was 16.9% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 58.54 versus an industry PE of 62.79, a de-rating toward the downside-risk PE of 46.83 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 27.7% below its 52-week high, with an RSI of 18.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Max Healthcare Institute

Start with the live price and volume. Any Max Healthcare Institute share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 883.80 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Max Healthcare Institute's PE, ROE, debt and shareholding in one place.

Check Max Healthcare Institute fundamentals on the Univest Screener

Then compare the three Max Healthcare Institute target price scenarios with your own view. If you expect EPS growth below 16.7%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Max Healthcare Institute live price and get daily stock recommendations.

Conclusion

The Max Healthcare Institute share price target for 2027 is Rs 1,023 in the base case, with Rs 1,237 as the bull case. The support for that view is arithmetic you can check: EPS grew 16.7% a year over FY24 to FY26, and the stock trades at a PE of 58.54. The risks are equally concrete, including a stock that sits 27.7% below its 52-week high and a downside scenario that cuts the price 21% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Max Healthcare Institute Share Price Target 2027

What is the Max Healthcare Institute share price target for 2027?

Ans. The base-case Max Healthcare Institute share price target for 2027 is Rs 1,023, with Rs 1,237 as the bull case. The downside risk level, which is not a target, is Rs 701. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Max Healthcare Institute share price today?

Ans. As of 9 October 2026, 3:30 PM IST, Max Healthcare Institute trades at Rs 883.80, up 1.19% on the day. The 52-week range is Rs 870.00 to Rs 1,221.90.

Is Max Healthcare Institute a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 16.7% a year over FY24 to FY26, but the stock is 27.7% below its 52-week high. Whether Max Healthcare Institute fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Max Healthcare Institute shares?

Ans. The bull case target is Rs 1,237, which assumes 22.7% EPS growth and a PE of 67.32. The downside risk level is Rs 701, which assumes flat EPS and a PE of 46.83. It marks a risk, not a target.

What are the main risks to the Max Healthcare Institute price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 85,291 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Max Healthcare Institute and how does it compare with the industry?

Ans. The PE ratio of Max Healthcare Institute is 58.54 against an industry PE of 62.79. Price to book is 7.94 and return on equity is 13.42%. The base case in the Max Healthcare Institute price target holds this PE constant.

Who owns Max Healthcare Institute, and what is the promoter holding?

Ans. Promoters held 23.71% of Max Healthcare Institute in June 2026. FII held 41.78%, DII held 29.96% and the public held 4.56%.

What were Max Healthcare Institute's latest quarterly results?

Ans. In the June 2026 quarter, Max Healthcare Institute reported revenue of Rs 2,407 crore (up 16.6% year on year) and net profit of Rs 322.96 crore (up 4.9%).